Relevant bibliographies by topics / Biological disease-modifying antirheumatic drugs (bDMARDs) / Journal articles
To see the other types of publications on this topic, follow the link: Biological disease-modifying antirheumatic drugs (bDMARDs).

Journal articles on the topic 'Biological disease-modifying antirheumatic drugs (bDMARDs)'

Author: Grafiati
Published: 7 June 2025
Last updated: 16 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Biological disease-modifying antirheumatic drugs (bDMARDs).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Bobkova, A. O., and A. M. Lila. "Switching biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in patients with rheumatoid arthritis." Modern Rheumatology Journal 17, no. 3 (2023): 82–88. http://dx.doi.org/10.14412/1996-7012-2023-3-82-88.

Full text
Abstract:
The goal of treatment of rheumatoid arthritis (RA) is to achieve remission or low disease activity. A wide range of disease-modifying antirheumatic drugs is used for the treatment of RA, including biological disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase inhibitors (JAKi). However, even with the use of bDMARDs and JAKi, this goal can be achieved only in 40–60% of patients. Insufficient response to bDMARs and JAKi is the reason for switching to other drugs from the same group, such as tumor necrosis factor-α inhibitors, and to drugs with a different mechanism of action. The ne
APA, Harvard, Vancouver, ISO, and other styles
2

Delpech, Célia, François-Xavier Larborne, and Pascal Hilliquin. "Comparison of Biological Agent Monotherapy and Associations Including Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis: Literature Review and Meta-Analysis of Randomized Trials." Journal of Clinical Medicine 12, no. 1 (2022): 286. http://dx.doi.org/10.3390/jcm12010286.

Full text
Abstract:
Objective: Update the available evidence comparing biologic disease-modifying antirheumatic drugs (bDMARDs) in combination with conventional synthetic disease-modifying antirheumatic drugs (CsDMARDs) to bDMARDs in monotherapy in patients with rheumatoid arthritis. Methods: Research was limited to randomized controlled trials. Major outcome: ACR 20 response criteria at 24 weeks. Secondary outcomes: clinical and radiographic criteria at week 24, 52 and 104. Results: 23 trials (6358 patients), including seven bDMARDs and one other molecule: Anbainuo (anti-TNF-R). No study satisfied our search cri
APA, Harvard, Vancouver, ISO, and other styles
3

Batozhargalova, B. Ts, N. A. Sagatbayeva, G. M. Abdullayeva, et al. "Immunogenicity of Pneumococcal Polysaccharide Vaccine in patients with rheumatoid arthritis." Journal Infectology 16, no. 4 (2024): 36–44. http://dx.doi.org/10.22625/2072-6732-2024-16-3-36-44.

Full text
Abstract:
The presented review searched for articles in the databases PubMed, Web of Science, Scopus, Google Scholar, eLibrary (2002-2022) and assessed the immunogenicity of the 23-valent polysaccharide pneumococcal vaccine (PPV23) in adult patients with rheumatoid arthritis (RA), receiving various antirheumatic drugs. The results of this review indicated sufficient immunogenicity of PPV23 in RA patients receiving monotherapy with various biological drugs (bDMARDs) (TNFα inhibitors, IL6 receptor inhibitors, T-lymphocyte costimulation blockers), targeted synthetic disease-modifying antirheumatic drugs (t
APA, Harvard, Vancouver, ISO, and other styles
4

Natour, Abd El Haleem, and Shaye Kivity. "Biological Therapies in Inflammatory Myopathies." Rambam Maimonides Medical Journal 14, no. 2 (2023): e0008. http://dx.doi.org/10.5041/rmmj.10495.

Full text
Abstract:
Idiopathic inflammatory myopathies (IIM) are a rare group of disorders that feature progressive immune-mediated skeletal muscle destruction along with skin, lung, and joint involvement. Management of IIMs necessitates glucocorticoid therapy followed by conventional steroid-sparing agents to control disease activity. In the settings of refractory myositis or life-threatening manifestations, e.g. lung involvement or oropharyngeal dysphagia, second-line therapies are needed to minimize disease burden, avoid end-organ damage and steroid toxicity, and decrease mortality. These therapies may include
APA, Harvard, Vancouver, ISO, and other styles
5

Strong, J., T. N. Mann, G. S. Tarr, and H. Reuter. "Development of active tuberculosis in patients treated with biological disease-modifying antirheumatic drugs." South African Medical Journal 112, no. 2 (2022): 76–80. http://dx.doi.org/10.7196/samj.2022.v112i2.16036.

Full text
Abstract:
Background. Biological disease-modifying antirheumatic drugs (bDMARDs) have been shown to be highly effective in the treatment of rheumatic conditions, but may increase the risk of infections. Development of tuberculosis (TB) while on bDMARD therapy is of particular concern in high TB burden settings such as Western Cape Province, South Africa. Objectives. To describe the diagnosis, management and outcome of patients who developed active TB while receiving a bDMARD. Results. Ten patients who screened negative for TB prior to initiation of a bDMARD subsequently developed active TB. TB was diagn
APA, Harvard, Vancouver, ISO, and other styles
6

Horneff, Gerd, Julia Borchert, Joanna Diesing, et al. "Treatment Patterns in Polyarticular Juvenile Idiopathic Arthritis: A Retrospective Observational Health Claims Data Study." Life 14, no. 6 (2024): 712. http://dx.doi.org/10.3390/life14060712.

Full text
Abstract:
(1) Background: Achieving inactive disease decreases long-term joint damage in patients with polyarticular juvenile idiopathic arthritis (polyJIA). The aim of our study was to describe average time to treatment and medication changes over time. (2) Methods: Incident polyJIA patients were retrospectively identified in the InGef and WIG2 longitudinal health claims databases. Drug escalation level changes were evaluated longitudinally and cross-sectionally across three years, as follows: no treatment, glucocorticoids (GCs) and/or non-steroidal anti-inflammatory drugs (NSAIDs), conventional synthe
APA, Harvard, Vancouver, ISO, and other styles
7

Cheema, Ahmed Ammar, Amer Fakhr, Muhammad Shahid Khan, Shanzah Shahbaz, Syed Nazir Ahmed, and Muhammad Zahid Hussain. "Comparison of Respiratory Complications of COVID-19 among Patients with Rheumatological Conditions Taking Biological Disease-Modifying Anti-Rheumatic Drugs and Conventional Synthetic Disease-Modifying Antirheumatic Drugs." Pakistan Armed Forces Medical Journal 72, no. 4 (2022): 1355–58. http://dx.doi.org/10.51253/pafmj.v72i4.4498.

Full text
Abstract:
Objective: To compare the respiratory complications of COVID-19 among patients with rheumatological conditions taking bDMARDs and csDMARDs at Pak Emirates Military Hospital Rawalpindi.
 Study Design: Comparative prospective study.
 Place and Duration of Study: Pak Emirates Military Hospital, Rawalpindi Pakistan from Mar to May 2020.
 Methodology: Patients diagnosed with COVID-19 on polymerase chain reaction having previously rheumatological conditions managed either with bDMARD or cs DMARD were included in the study. They were followed up for three weeks after the positive polym
APA, Harvard, Vancouver, ISO, and other styles
8

Fedele, A. L., F. Melpignano, D. Bruno, R. La Ferrara, and M. A. D’agostino. "POS0662 BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS PRESCRIPTION OVER TIME IN A COHORT OF EARLY RHEUMATOID ARTHRITIS PATIENTS." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 603.2–603. http://dx.doi.org/10.1136/annrheumdis-2022-eular.5285.

Full text
Abstract:
BackgroundAccording to 2019 updated EULAR recommendations, therapy of Early Rheumatoid Arthritis (ERA) with biological disease-modifying antirheumatic drugs(bDMARDs) is adviced in presence of poor prognostic factors,i.e. persistently moderate/high disease activity, high acute phase reactants, high swollen joint count, autoantibody positivity, presence of early erosions, failure of two/more conventional synthetic DMARD.ObjectivesTo evaluate over time prevalence of bDMARD therapy and factors associated to rapid initiation in our EA Clinic (EAC), comparing two different periods: from 2004 to 2012
APA, Harvard, Vancouver, ISO, and other styles
9

Smolen, Josef S., Robert Landewé, Ferdinand C. Breedveld, et al. "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update." Annals of the Rheumatic Diseases 73, no. 3 (2013): 492–509. http://dx.doi.org/10.1136/annrheumdis-2013-204573.

Full text
Abstract:
In this article, the 2010 European League against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis (RA) with synthetic and biological disease-modifying antirheumatic drugs (sDMARDs and bDMARDs, respectively) have been updated. The 2013 update has been developed by an international task force, which based its decisions mostly on evidence from three systematic literature reviews (one each on sDMARDs, including glucocorticoids, bDMARDs and safety aspects of DMARD therapy); treatment strategies were also covered by the searches. The evidence presented was discussed and
APA, Harvard, Vancouver, ISO, and other styles
10

Gadzhanova, Svetla, and Elizabeth Roughead. "Use of Analgesic and Anti-Inflammatory Medicines before and after Initiation of Biological Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis." Journal of Clinical Pharmacy and Therapeutics 2024 (February 23, 2024): 1–7. http://dx.doi.org/10.1155/2024/8040681.

Full text
Abstract:
Background. Rheumatoid arthritis (RA) is an inflammatory condition that causes joint damage and is associated with pain. The biological disease-modifying antirheumatic drugs (bDMARDs) for RA are linked to additional therapeutic benefits as they suppress the inflammatory process, which in turn prevents joint erosion and reduces pain. Thus, the use of bDMARDs has the potential to reduce the need for other analgesic and anti-inflammatory therapies for RA. The aim of this study was to examine the analgesic and anti-inflammatory use around the initiation of bDMARDs. Methods. A cohort study was cond
APA, Harvard, Vancouver, ISO, and other styles
11

Weng, Chenghua, Leixi Xue, Qing Wang, Wentian Lu, Jiajun Xu, and Zhichun Liu. "Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis." Therapeutic Advances in Musculoskeletal Disease 13 (January 2021): 1759720X2199956. http://dx.doi.org/10.1177/1759720x21999564.

Full text
Abstract:
Objective: To evaluate the comparative efficacy and safety of Janus kinase (JAK) inhibitors and biological disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) and an inadequate response to at least one disease-modifying antirheumatic drug (DMARD). Methods: PubMed, Embase, Cochrane library and ClinicalTrials.gov were searched for relevant randomized controlled trials (RCTs) from inception to April 2020. The active drugs included three JAK inhibitors and eight bDMARDs while the control drugs included placebo or conventional synthetic disease-modifying antir
APA, Harvard, Vancouver, ISO, and other styles
12

Ichinose, Kunihiro, Toshimasa Shimizu, Masataka Umeda, et al. "Frequency of Hospitalized Infections Is Reduced in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs after 2010." Journal of Immunology Research 2018 (August 14, 2018): 1–8. http://dx.doi.org/10.1155/2018/6259010.

Full text
Abstract:
Background. Biological disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic (ts) DMARDs are important in rheumatoid arthritis (RA) treatment. The risk of hospitalized infection associated with bDMARDs/tsDMARDs in RA patients is unclear. Methods. We retrospectively analyzed the cases of the 275 RA patients with 449 treatment episodes who were administered a bDMARD/tsDMARD at Nagasaki University Hospital in July 2003–January 2015. We determined the incidence and risk factors of infection requiring hospitalization in the patients during a 3-year observation period. Results. Thir
APA, Harvard, Vancouver, ISO, and other styles
13

Martins, A., D. Santos Oliveira, F. R. Martins, et al. "AB0439 ADALIMUMAB AND NUMBER OF PREVIOUS BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AS PREDICTIVE FACTORS FOR THE DEVELOPMENT OF IMMUNE-MEDIATED SKIN LESIONS." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 1408.1–1408. http://dx.doi.org/10.1136/annrheumdis-2023-eular.2061.

Full text
Abstract:
BackgroundTreatment of inflammatory rheumatic diseases has dramatically changed with the introduction of biologic disease modifying anti-rheumatic drugs (bDMARDs). However, these drugs aren’t exempt from risks and skin lesions are the most frequent adverse reactions. Among the possible adverse skin reactions, immune-mediated skin lesions (IMSL) may occur. Risk factors associated with the occurrence of IMSL in rheumatic patients under bDMARDs are poorly known and studied.ObjectivesTo identify predictive factors for IMSL in patients with rheumatoid arthritis (RA), axial spondyloarthritis (axSpA)
APA, Harvard, Vancouver, ISO, and other styles
14

Perković, Dijana, Marin Petrić, Maja Maleš, Ivana Erceg Maleš, and Mislav Radić. "Biological Disease-Modifying Antirheumatic Drugs Decrease Uric Acid Levels in the Sera of Patients with Psoriatic Arthritis." Current Issues in Molecular Biology 47, no. 3 (2025): 142. https://doi.org/10.3390/cimb47030142.

Full text
Abstract:
Objectives: There are many explanations for increased levels of serum uric acid (SUA) in patients with psoriatic arthritis (PsA), but correlation with different treatment options in PsA is not well elucidated. Our aim was to determine the effects of biological disease-modifying antirheumatic drugs (bDMARDs) on SUA levels in patients with PsA. Materials and methods: We analyzed the data of PsA patients treated with different bDMARDs from January 2007 to June 2021. Patients treated with interleukin-17 (IL-17) inhibitors (secukinumab and ixekizumab) and tumor necrosis factor α (TNFα) inhibitors (
APA, Harvard, Vancouver, ISO, and other styles
15

Hu, Suiyuan, Chu Lin, Xiaoling Cai, et al. "The Biological Disease-Modifying Antirheumatic Drugs and the Risk of Cardiovascular Events: A Systematic Review and Meta-Analysis." Mediators of Inflammation 2021 (August 31, 2021): 1–12. http://dx.doi.org/10.1155/2021/7712587.

Full text
Abstract:
Objective. To assess the association between the use of biological disease-modifying antirheumatic drugs (bDMARDs) and the risk of cardiovascular events in patients with systemic inflammatory conditions. Methods. Eligible cohort studies or randomized controlled trials (RCTs) from inception to January 2021 were included. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) for cardiovascular outcomes were calculated in the fixed- and random-effects model accordingly. Associated factors with risks of cardiovascular events were also studied in sensitivity analyses and metaregression analy
APA, Harvard, Vancouver, ISO, and other styles
16

Musaeva, Larisa M., Irina V. Menshikova, Svetlana A. Appolonova, and Ksenya M. Shestakova. "Metabolomic changes in rheumatoid arthritis: focus on biological disease-modifying antirheumatic drugs." Clinical review for general practice 5, no. 11 (2024): 62–69. https://doi.org/10.47407/kr2024.5.11.00518.

Full text
Abstract:
Background. Rheumatoid arthritis (RA) is a systemic chronic autoimmune disease characterized by erosive and destructive joint lesions leading to their ankylosis, as well as damage to other organs and systems. The main types of RA treatment are reducing the severity of pain, slowing the rate of disease progression and improving the quality of life of patients. Despite advances in the treatment of RA, few significant biomarkers have been identified to date for the diagnosis and effectiveness of drug therapy control in RA. The results of scientific studies have shown that the pathogenesis of RA i
APA, Harvard, Vancouver, ISO, and other styles
17

Silvagni, Ettore, Alessandra Bortoluzzi, Greta Carrara, Anna Zanetti, Marcello Govoni, and Carlo Alberto Scirè. "Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases." BMJ Open 8, no. 9 (2018): e021447. http://dx.doi.org/10.1136/bmjopen-2017-021447.

Full text
Abstract:
ObjectiveThese analyses aim to comparatively evaluate the persistence on treatment of different biological disease-modifying antirheumatic drugs (bDMARDs) when administered in monotherapy compared with combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in rheumatoid arthritis (RA) patients receiving first-line biologics.DesignThis is a retrospective observational study on Administrative Healthcare Databases.MethodsData were extracted from healthcare databases of the Lombardy Region, Italy (2004–2013), as a part of the RECord-linkage On Rheumatic Diseases s
APA, Harvard, Vancouver, ISO, and other styles
18

Bettuzzi, Thomas, Hervé Bachelez, Marie Beylot-Barry, et al. "Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Patients with Psoriasis from the PsoBioTeq Cohort." Acta Dermato-Venereologica 102 (March 8, 2022): adv00665. http://dx.doi.org/10.2340/actadv.v101.566.

Full text
Abstract:
Drug survival reflects treatment effectiveness and safety in real life. There is limited data on the variation of drug survival with the availability of systemic treatments with additional biological disease-modifying antirheumatic drugs (bDMARDs) or synthetic disease-modifying antirheumatic drugs (sDMARDs). The aim of this study was to determine whether the increasing number of available systemic treatments for psoriasis affects drug survival over time. Patients were selected from the PsoBioTeq cohort, a French prospective observational cohort enrolling patients with moderate to severe psoria
APA, Harvard, Vancouver, ISO, and other styles
19

Nam, Jackie L., Kaoru Takase-Minegishi, Sofia Ramiro, et al. "Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis." Annals of the Rheumatic Diseases 76, no. 6 (2017): 1113–36. http://dx.doi.org/10.1136/annrheumdis-2016-210713.

Full text
Abstract:
ObjectivesTo update the evidence for the efficacy of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) to inform European League Against Rheumatism (EULAR) Task Force treatment recommendations.MethodsMEDLINE, EMBASE and Cochrane databases were searched for phase III or IV (or phase II, if these studies were lacking) randomised controlled trials (RCTs) published between January 2013 and February 2016. Abstracts from the American College of Rheumatology and EULAR conferences were obtained.ResultsThe RCTs confirmed greater efficacy with a bDMARD
APA, Harvard, Vancouver, ISO, and other styles
20

Salugina, S. O., E. S. Fedorov, and M. I. Kaleda. "Biological disease-modifying antirheumatic drugs in the main monogenic autoinflammatory diseases treatment. Experience of application in rheumatological practice." Modern Rheumatology Journal 15, no. 4 (2021): 24–30. http://dx.doi.org/10.14412/1996-7012-2021-4-24-30.

Full text
Abstract:
Objective: to assess the frequency of prescription, efficacy and tolerability of biological disease-modifying antirheumatic drugs (bDMARDs) therapy in patients with major monogenic autoinflammatory diseases (mAID) according to the Federal Rheumatology Center clinical practice. Patients and methods. From 2008 to 2020 years, 158 patients with mAID were included in the study, 53 of whom were prescribed bDMARDs: 12 patients had Familial Mediterranean Fever (FMF); 26 – Cryopyrin-Associated Periodic Syndromes (CAPS), including 21 patients with MuckleWells Syndrome (MWS) and 5 – with Chronic Infantil
APA, Harvard, Vancouver, ISO, and other styles
21

Uhrenholt, Line, Annette Schlemmer, Ellen-Margrethe Hauge, et al. "Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial)." BMJ Open 9, no. 7 (2019): e028517. http://dx.doi.org/10.1136/bmjopen-2018-028517.

Full text
Abstract:
IntroductionThe The BIOlogical Dose OPTimisation (BIODOPT) trial is a pragmatic, multicentre, randomised controlled, open-label, parallel-group, equivalence study designed to evaluate tapering of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) in sustained clinical remission or low disease activity (LDA). Traditionally, these patients maintain standard dosage of bDMARD lifelong; however, recent studies indicate that a significant proportion of patients in sustained remission or
APA, Harvard, Vancouver, ISO, and other styles
22

Mazurov, V. I., A. M. Lila, and T. V. Korotaeva. "Erelzi® – biosimilar of etanercept in the treatment of rheumatic diseases and psoriasis (Resolution of the Expert Panel)." Modern Rheumatology Journal 15, no. 4 (2021): 129–31. http://dx.doi.org/10.14412/1996-7012-2021-4-129-131.

Full text
Abstract:
Introduction of biosimilars of biological disease-modifying antirheumatic drugs (bDMARs) into clinical practice has significantly expanded the availability of bDMARD therapy for a wide range of patients with chronic immuno-inflammatory diseases.In 2020, the first biosimilar etanercept Erelzi®, was registered in the Russian Federation. On May 22, 2021, an interdisciplinary Expert panel meeting was held on the use of Erelzi® for the treatment of rheumatic diseases and psoriasis. The leading Russian rheumatologists and dermatologists participated in this meeting. In the resolution of the Expert p
APA, Harvard, Vancouver, ISO, and other styles
23

Martins, A., D. Santos Oliveira, F. R. Martins, et al. "AB0395 IMMUNE-MEDIATED SKIN LESIONS RELATED TO BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: A 22-YEAR EXPERIENCE OF A TERTIARY CENTER." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 1381.1–1381. http://dx.doi.org/10.1136/annrheumdis-2023-eular.2044.

Full text
Abstract:
BackgroundBiological disease-modifying antirheumatic drugs (bDMARDs) have revolutionized the treatment of chronic inflammatory rheumatic diseases. However, the physician and the patient should be aware of possible adverse reactions. Skin is one of the most frequent organs involved in bDMARD adverse reactions and immune-mediated skin lesions (IMSL) have rarely been described before in cohort studies and their incidence is unknown.ObjectivesTo explore the cumulative incidence, type of lesions, management and outcomes of IMSL related to bDMARD in a large cohort of patients with rheumatoid arthrit
APA, Harvard, Vancouver, ISO, and other styles
24

Akter, Ripa, Walter P. Maksymowych, M. Liam Martin, and David B. Hogan. "Outcomes with Biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in Older Patients Treated for Rheumatoid Arthritis." Canadian Geriatrics Journal 23, no. 2 (2020): 184–89. http://dx.doi.org/10.5770/cgj.23.393.

Full text
Abstract:
Background
 Biological disease-modifying antirheumatic drugs (bDMARDs) are recommended for rheumatoid arthritis (RA), but older patients reportedly experience more adverse events (AEs) and show variable treatment response. The objective of this study was to evaluate AEs and effectiveness of bDMARDs in a cohort of older patients.
 Methods
 AE and treatment effectiveness (based on DAS28 scores) data from a prospective provincial pharmacovigilance program for the years 2006–2009 in patients 55–64, 65–74, and 75+ years of age were compared. An intention to treat analysis with chisqu
APA, Harvard, Vancouver, ISO, and other styles
25

Seeliger, Benjamin, and Antje Prasse. "Immunomodulation in Autoimmune Interstitial Lung Disease." Respiration 99, no. 10 (2020): 819–29. http://dx.doi.org/10.1159/000511200.

Full text
Abstract:
Interstitial lung diseases (ILDs) associated with autoimmune or systemic disease are increasingly recognized and our pathophysiological understanding rapidly expanding. Treatment modalities, however, are still mainly driven by established disease-modifying antirheumatic drugs (DMARDs) where, despite decades of experience of their use in the underlying diseases such as rheumatoid arthritis, mostly ret­rospective data exist informing their effect on the course of interstitial lung disease (ILD). In recent years, randomized trials investigating the effects of biological DMARDs (bDMARDs) have been
APA, Harvard, Vancouver, ISO, and other styles
26

Takei, Hiroshi, Naoshi Nishina, Ho Namkoong, et al. "Rheumatoid arthritis with nontuberculous mycobacterial pulmonary disease: a retrospective, single-centre cohort study." Modern Rheumatology 32, no. 3 (2021): 534–40. http://dx.doi.org/10.1093/mr/roab032.

Full text
Abstract:
ABSTRACT Objectives Nontuberculous mycobacterial pulmonary disease (NTM-PD) is a rare but important comorbidity of rheumatoid arthritis (RA). Our objective was to investigate the association between NTM-PD and RA, especially regarding the immunosuppressive treatment of RA such as biological disease-modifying antirheumatic drugs (bDMARDs). Methods We conducted a retrospective, single-centre cohort study. All RA patients regularly followed up at our rheumatology division in December 2012 were included in the study, and followed for 5 years. Results At baseline, 26 of 1639 RA patients had NTM-PD.
APA, Harvard, Vancouver, ISO, and other styles
27

Gossec, Laure, Xenofon Baraliakos, Andreas Kerschbaumer, et al. "EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update." Annals of the Rheumatic Diseases 79, no. 6 (2020): 700–712. http://dx.doi.org/10.1136/annrheumdis-2020-217159.

Full text
Abstract:
ObjectiveTo update the European League Against Rheumatism (EULAR) recommendations for the pharmacological treatment of psoriatic arthritis (PsA).MethodsAccording to the EULAR standardised operating procedures, a systematic literature review was followed by a consensus meeting to develop this update involving 28 international taskforce members in May 2019. Levels of evidence and strengths of recommendations were determined.ResultsThe updated recommendations comprise 6 overarching principles and 12 recommendations. The overarching principles address the nature of PsA and diversity of both muscul
APA, Harvard, Vancouver, ISO, and other styles
28

Salehi, Fatemeh, Luis I. Lopera Gonzalez, Sara Bayat, et al. "Machine Learning Prediction of Treatment Response to Biological Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis." Journal of Clinical Medicine 13, no. 13 (2024): 3890. http://dx.doi.org/10.3390/jcm13133890.

Full text
Abstract:
Background: Disease-modifying antirheumatic drugs (bDMARDs) have shown efficacy in treating Rheumatoid Arthritis (RA). Predicting treatment outcomes for RA is crucial as approximately 30% of patients do not respond to bDMARDs and only half achieve a sustained response. This study aims to leverage machine learning to predict both initial response at 6 months and sustained response at 12 months using baseline clinical data. Methods: Baseline clinical data were collected from 154 RA patients treated at the University Hospital in Erlangen, Germany. Five machine learning models were compared: Extre
APA, Harvard, Vancouver, ISO, and other styles
29

Brito, Carlos A. A. de, Claudia D. L. Marques, Rafael F. O. França, et al. "Reduced Duration of Postchikungunya Musculoskeletal Pain in Rheumatological Patients Treated with Biologicals." Journal of Tropical Medicine 2020 (July 10, 2020): 1–6. http://dx.doi.org/10.1155/2020/2071325.

Full text
Abstract:
Chikungunya fever (CHIK) has caused important epidemic outbreaks in the Americas, with musculoskeletal involvement being the main manifestation, causing chronic symptoms in half of the affected patients. This study was performed to evaluate the clinical course of the infection in 168 patients with autoimmune inflammatory disease using biological disease-modifying antirheumatic drugs (bDMARDs), comparing this group with 56 household controls. Anti-CHIKV IgG serology was positive in 42 (25%) of the patients in the bDMARD group and in 15 (27%) of the controls (p=0.79). Of those with positive sero
APA, Harvard, Vancouver, ISO, and other styles
30

Leon, Leticia, Marina Peñuelas, Francisco Javier Candel, et al. "Indicator opportunistic infections after biological treatment in rheumatoid arthritis, 10 years follow-up in a real-world setting." Therapeutic Advances in Musculoskeletal Disease 11 (January 2019): 1759720X1987800. http://dx.doi.org/10.1177/1759720x19878004.

Full text
Abstract:
Background: This research describes the incidence and factors associated with opportunistic infections in rheumatoid arthritis (RA) patients treated with biological disease-modifying antirheumatic drugs (bDMARDs). Methods: A retrospective longitudinal study was carried out from 2007 to 2018. We included RA patients treated with a tumor necrosis factor (TNF)-targeted bDMARD or non-TNF-targeted bDMARD from the start of bDMARDs. An independent variable was the development of an indicator of opportunistic infection after biological (IOIb) treatment. Secondary variables included sociodemographic, c
APA, Harvard, Vancouver, ISO, and other styles
31

Sugimori, Kazuhito, Isao Matsushita, and Tomoatsu Kimura. "Evaluating various radiographic methods of shoulder joint damage in patients with rheumatoid arthritis receiving biological disease-modifying antirheumatic drugs." Archives of Rheumatology 36, no. 3 (2020): 349–59. http://dx.doi.org/10.46497/archrheumatol.2021.8236.

Full text
Abstract:
Objectives: This study aims to clarify shoulder joint damage in rheumatoid arthritis patients receiving biological disease-modifying antirheumatic drugs (bDMARDs) and the relationship between joint damage and clinical factors. Patients and methods: In this retrospective study conducted between April 2005 and December 2008, 36 shoulders in 19 patients (2 males, 17 females; mean age: 58.9 years; range 42 to 75 years) were evaluated at baseline and two years after the initiation of bDMARD therapy with infliximab (n=14) or etanercept (n=5). Standard anteroposterior radiographs of the shoulder join
APA, Harvard, Vancouver, ISO, and other styles
32

Erdes, Sh F., K. V. Sakharova, T. V. Dubinina, and M. V. Cherkasova. "Clinical features of patients with ankylosing spondylitis with inefficacy of two or more biological disease modifying antirheumatic drugs." Modern Rheumatology Journal 17, no. 3 (2023): 30–36. http://dx.doi.org/10.14412/1996-7012-2023-3-30-36.

Full text
Abstract:
The “Treat-to-target” (T2T) strategy for axial spondyloarthritis (axSpA) has made it possible to optimize therapy in most patients, but in some of them the treatment goals are not achieved.Objective: to analyze the clinical features of patients with ankylosing spondylitis (AS) with inefficacy of two or more biological disease modifying antirheumatic drugs (bDMARDs).Material and methods. From February 2020 to March 2022 458 patients with AS, who met the modified New York criteria of 1984, were admitted to V.A. Nasonova Research Institute of Rheumatology. From this group, 30 (6.6%) patients with
APA, Harvard, Vancouver, ISO, and other styles
33

Mori, Shunsuke, Akitomo Okada, Tomohiro Koga, and Yukitaka Ueki. "Long-term outcomes after discontinuing biological drugs and tofacitinib in patients with rheumatoid arthritis: A prospective cohort study." PLOS ONE 17, no. 6 (2022): e0270391. http://dx.doi.org/10.1371/journal.pone.0270391.

Full text
Abstract:
Objective This study examined long-term outcomes of biological disease-modifying antirheumatic drugs (bDMARDs) and tofacitinib discontinuation in patients with rheumatoid arthritis (RA). Methods Ninety-seven RA patients who desired drug discontinuation after sustained remission or low disease activity for at least 48 weeks due to stable treatment with biological drugs or tofacitinib were enrolled into this study. All patients were prospectively followed until disease flare or the end of the study. Discontinued drugs (previous drugs) were reintroduced to treat flares. Results Following bDMARD/t
APA, Harvard, Vancouver, ISO, and other styles
34

Dreyer, Lene, René L. Cordtz, Inger Marie J. Hansen, Lars Erik Kristensen, Merete L. Hetland, and Lene Mellemkjaer. "Risk of second malignant neoplasm and mortality in patients with rheumatoid arthritis treated with biological DMARDs: a Danish population-based cohort study." Annals of the Rheumatic Diseases 77, no. 4 (2017): 510–14. http://dx.doi.org/10.1136/annrheumdis-2017-212086.

Full text
Abstract:
ObjectiveTo study the risk of a second malignant neoplasm (SMN) and mortality in patients with rheumatoid arthritis (RA) with a history of a primary cancer diagnosis and treated with biological disease-modifying antirheumatic drugs (bDMARD).MethodsAmong patients with RA (n=15 286) registered in the DANBIO Register during 2000–2011, 1678 had a primary cancer according to the Danish Cancer Registry. HRs for SMN and death were calculated.ResultsDuring follow-up there were 279 patients with RA contributing person-years to the bDMARDs use before their primary cancer diagnosis, 220 to the only after
APA, Harvard, Vancouver, ISO, and other styles
35

Rastogi, Dheeraj, Partha P. Das, and Manish Khanna. "Systemic review of safety and efficacy of approved bio similar for management of rheumatoid arthritis." Indian Journal of Orthopaedics Surgery 10, no. 1 (2024): 1–8. http://dx.doi.org/10.18231/j.ijos.2024.001.

Full text
Abstract:
Biological medicines have opened up new doors to treat many diseases, which include cancers, autoimmune conditions, diabetes, and so on. Stem-cell and gene therapies, insulin, and monoclonal antibodies are all some of the many instances of biological therapies.Biological Disease-modifying antirheumatic drugs (bDMARDs), such as monoclonal antibodies and receptor Fc-fusion proteins that target the tumor necrosis factor (TNF), are the recent development in treatment for patients with rheumatic conditions.Patients who are inadequate respondents to stand-alone conventional synthetic DMARDs have sig
APA, Harvard, Vancouver, ISO, and other styles
36

Bower, Hannah, Thomas Frisell, Daniela di Giuseppe, et al. "Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision." RMD Open 7, no. 3 (2021): e001987. http://dx.doi.org/10.1136/rmdopen-2021-001987.

Full text
Abstract:
ObjectivesTo compare risks for COVID-19-related outcomes in inflammatory joint diseases (IJDs) and across disease-modifying antirheumatic drugs (DMARDs) during the first two waves of the pandemic and to assess effects of the pandemic on rheumatology care provision.MethodsThrough nationwide multiregister linkages and cohort study design, we defined IJD and DMARD use annually in 2015–2020. We assessed absolute and relative risks of hospitalisation or death listing COVID-19. We also assessed the incidence of IJD and among individuals with IJD, rheumatologist visits, DMARD use and incidence of sel
APA, Harvard, Vancouver, ISO, and other styles
37

Smolen, Josef S., Joao Goncalves, Mark Quinn, Fabrizio Benedetti, and Jake Yongkwon Lee. "Era of biosimilars in rheumatology: reshaping the healthcare environment." RMD Open 5, no. 1 (2019): e000900. http://dx.doi.org/10.1136/rmdopen-2019-000900.

Full text
Abstract:
Compared with the original approved biological drug on which it is based, a biosimilar has highly similar physicochemical characteristics and biological activity, as well as equivalent efficacy and no clinically meaningful differences in safety and immunogenicity. Before they are approved, biosimilars must undergo a rigorous development process using state-of-the-art technologies to establish biosimilarity to the reference biological product. After approval, biosimilars must comply with good pharmacological practices for biological drugs. Several biosimilar disease-modifying antirheumatic drug
APA, Harvard, Vancouver, ISO, and other styles
38

Ingrasciotta, Ylenia, Valentina Isgrò, Valentina Ientile, Michele Tari, Gianluca Trifirò, and Claudio Guarneri. "Are Patients with Psoriasis and Psoriatic Arthritis Undertreated? A Population-Based Study from Southern Italy." Journal of Clinical Medicine 10, no. 15 (2021): 3431. http://dx.doi.org/10.3390/jcm10153431.

Full text
Abstract:
This study aimed to explore the pattern of use of different treatment lines in psoriasis (PsO) and psoriatic arthritis (PsA) patients from Southern Italy. A retrospective cohort study was performed during the years 2010–2018 using data from the Caserta Local Health Unit (LHU) claims database. All of the PsO or PsA patients were identified. The proportion of PsO/PsA patients untreated or treated with ≥1 drug classes (i.e., non-disease-modifying antirheumatic drugs (non-DMARDs), conventional synthetic DMARDs (csDMARDs), biological drugs (bDMARDs) or targeted synthetic small molecules (tsDMARDs))
APA, Harvard, Vancouver, ISO, and other styles
39

Nikiphorou, Elena, Désirée van der Heijde, Sam Norton, et al. "Inequity in biological DMARD prescription for spondyloarthritis across the globe: results from the ASAS-COMOSPA study." Annals of the Rheumatic Diseases 77, no. 3 (2017): 405–11. http://dx.doi.org/10.1136/annrheumdis-2017-212457.

Full text
Abstract:
ObjectivesThe value of biological disease-modifying antirheumatic drugs (bDMARDs) in spondyloarthritis (SpA) is well recognised, but global access to these treatments can be limited due to high costs and other factors. This study explores country variation in the use of bDMARDs in SpA in relation to country-level socioeconomic factors.MethodsPatients fulfilling the Assessment in SpondyloArthritis International Society (ASAS) SpA criteria in the multinational, cross-sectional ASAS Comorbidities in Spondyloarthritis study were studied. Current use of bDMARDs or conventional synthetic DMARDs (csD
APA, Harvard, Vancouver, ISO, and other styles
40

Adami, Giovanni, Angelo Fassio, Maurizio Rossini, et al. "Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)." RMD Open 9, no. 1 (2023): e002792. http://dx.doi.org/10.1136/rmdopen-2022-002792.

Full text
Abstract:
IntroductionGlucocorticoids are still a mainstream of rheumatoid arthritis (RA) treatment. Reducing glucocorticoids should be attempted in all patients. However, choosing the right tapering strategy is challenging. The primary aim of our study is to determine the dose–response association between glucocorticoid tapering and risk of flare in RA.MethodsWe conducted a case-crossover study to determine the factors associated to higher risk of flare in patients with RA. In case-crossover studies time-varying factors are assessed before events (hazard periods) and before control periods. We defined
APA, Harvard, Vancouver, ISO, and other styles
41

Bower, Hannah, Thomas Frisell, Daniela Di Giuseppe, Bénédicte Delcoigne, and Johan Askling. "Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19?" Annals of the Rheumatic Diseases 81, no. 3 (2021): 433–39. http://dx.doi.org/10.1136/annrheumdis-2021-221461.

Full text
Abstract:
ObjectivesTo estimate absolute and relative risks for seasonal influenza outcomes in patients with inflammatory joint diseases (IJDs) and disease-modifying antirheumatic drugs (DMARDs). To contextualise recent findings on corresponding COVID-19 risks.MethodsUsing Swedish nationwide registers for this cohort study, we followed 116 989 patients with IJD and matched population comparators across four influenza seasons (2015–2019). We quantified absolute risks of hospitalisation and death due to influenza, and compared IJD to comparators via Cox regression. We identified 71 556 patients with IJD o
APA, Harvard, Vancouver, ISO, and other styles
42

Yazici, A., E. Dalkiliç, M. Birlik, et al. "SAT0544 USE OF BIOLOGICAL DMARDS IN PATIENTS WITH ADULT-ONSET STILL’S DISEASE: RESULTS FROM TURKBIO REGISTRY." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1229.1–1229. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3850.

Full text
Abstract:
Background:Adult-onset Still’s disease (AOSD) is a rare multisystemic inflammatory disorder, and is diagnosed by exclusion. AOSD is generally treated with nonsteroidal antiinflammatory drugs, corticosteroids, and conventional disease modifiying antirheumatic drugs (cDMARDs). Biological disease modifiying antirheumatic drug (bDMARD) therapy are recommended in AOSD patients who are refractory to tradional therapy, and bDMARDs is becoming increasingly important in AOSD treatment.Objectives:To evaluate the use of bDMARDs and drug survival in AOSD patients.Methods:TURKBIO registry is the Turkish ve
APA, Harvard, Vancouver, ISO, and other styles
43

Karpouzas, George Athanasios, Sarah R. Ormseth, Piet Leonardus Cornelis Maria van Riel, et al. "Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis." RMD Open 10, no. 3 (2024): e004546. http://dx.doi.org/10.1136/rmdopen-2024-004546.

Full text
Abstract:
ObjectivesChronic inflammation promotes cardiovascular risk in rheumatoid arthritis (RA). Biological disease-modifying antirheumatic drugs (bDMARDs) improve disease activity and cardiovascular disease outcomes. We explored whether bDMARDs influence the impact of disease activity and inflammatory markers on long-term cardiovascular risk in RA.MethodsWe studied 4370 participants without cardiovascular disease in a 10-country observational cohort of patients with RA. Endpoints were (1) major adverse cardiovascular events (MACE) encompassing myocardial infarction, stroke and cardiovascular death;
APA, Harvard, Vancouver, ISO, and other styles
44

Lopez-Pedrera, Chary, Nuria Barbarroja, Alejandra M. Patiño-Trives, et al. "Effects of Biological Therapies on Molecular Features of Rheumatoid Arthritis." International Journal of Molecular Sciences 21, no. 23 (2020): 9067. http://dx.doi.org/10.3390/ijms21239067.

Full text
Abstract:
Rheumatoid arthritis (RA) is an autoimmune and chronic inflammatory disease primarily affecting the joints, and closely related to specific autoantibodies that mostly target modified self-epitopes. Relevant findings in the field of RA pathogenesis have been described. In particular, new insights come from studies on synovial fibroblasts and cells belonging to the innate and adaptive immune system, which documented the aberrant production of inflammatory mediators, oxidative stress and NETosis, along with relevant alterations of the genome and on the regulatory epigenetic mechanisms. In recent
APA, Harvard, Vancouver, ISO, and other styles
45

Koehm, Michaela, Maximilian Klippstein, Stephanie Dauth, et al. "Impact of different classes of immune-modulating treatments on B cell-related and T cell-related immune response before and after COVID-19 booster vaccination in patients with immune-mediated diseases and primary immunodeficiency: a cohort study." RMD Open 9, no. 3 (2023): e003094. http://dx.doi.org/10.1136/rmdopen-2023-003094.

Full text
Abstract:
ObjectivesTo evaluate the potential of immunosuppressed patients to mount B-cell and T-cell responses to COVID-19 booster vaccination (third vaccination).MethodsPatients with primary immunodeficiency (PID), immune-mediated inflammatory diseases (IMIDs) on CD20-depleting treatment with rituximab (RTX), or IMIDs treated with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or biological disease-modifying antirheumatic drug (bDMARDs) were included and assessed before (baseline visit (BL)) and 2, 4 and 8 weeks after COVID-19 booster vaccination. Serum B-cell responses were a
APA, Harvard, Vancouver, ISO, and other styles
46

Karateev, A. E., A. M. Lila, T. S. Panevin, et al. "Dynamics of patient reported outcomes during the use various biological disease-modifying antirheumatic drugs for rheumatoid arthritis." Rheumatology Science and Practice 60, no. 4 (2022): 427–37. http://dx.doi.org/10.47360/1995-4484-2022-427-437.

Full text
Abstract:
One of the main tasks of modern complex therapy of rheumatoid arthritis (RA) is to improve the quality of life of patients. To do this, it is necessary not only to achieve remission or low activity, but also to successfully control the main, most painful, manifestations of the disease. Therefore, when evaluating the results of RA treatment, the dynamics of not only standard indices (DAS28 (Disease Activity Score 28), CDAI (Clinical Disease Activity Index), SDAI (Simplified Disease Activity Index)), but also the so-called “patient reported outcomes” (PRO) – a patient’s global assessment of dise
APA, Harvard, Vancouver, ISO, and other styles
47

Rozochkina, E., E. Koltsova, G. Lukina, et al. "AB0475 COMPARATIVE EFFECTIVENESS OF BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN REAL CLINICAL PRACTICE ACCORDING TO THE MOSCOW UNIFIED ARTHRITIS REGISTER (MUAR)." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 1265.1–1265. http://dx.doi.org/10.1136/annrheumdis-2021-eular.2819.

Full text
Abstract:
Background:This study is the first analysis of biological disease-modifying antirheumatic drugs (bDMARDs) for ankylosing spondylitis (AS) within the Moscow Unified Arthritis Register (MUAR).Objectives:to compare the effectiveness of bDMARDs in patients with AS using data from the MUAR.Methods:The analysis included the data of patients with AS who were included in the MUAR and received biological therapy for at least 6 months. The effectiveness of the drugs was assessed by the achieved values of the indices of diseases activity and its manifestations: ASDAS(C-RP), BASDAI, LEI, MASES, indicators
APA, Harvard, Vancouver, ISO, and other styles
48

Bixio, R., A. Milanesi, O. Viapiana, C. Montecucco, S. Bugatti, and M. Rossini. "AB0900 A temporary antirheumatic drugs withdrawal does not cause an excess of disease flares in patients with psoriatic arthritis undergoing Covid-19 mRNA vaccination." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 1578.2–1579. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2094.

Full text
Abstract:
BackgroundThe best way to manage disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatic and musculoskeletal diseases (RMDs) undergoing the Coronavirus disease (Covid)-19 vaccination and the recommendations regarding the use and timing of immunomodulatory therapies around the time of vaccination are still a matter of debate, due to the difficulties in balancing the vaccination efficacy and safety.ObjectivesTo assess the impact of different strategies of antirheumatic treatment management on disease activity around the time of vaccination for Coronavirus disease (Covid)-19 in
APA, Harvard, Vancouver, ISO, and other styles
49

Smolen, Josef S., Robert Landewé, Johannes Bijlsma, et al. "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update." Annals of the Rheumatic Diseases 76, no. 6 (2017): 960–77. http://dx.doi.org/10.1136/annrheumdis-2016-210715.

Full text
Abstract:
Recent insights in rheumatoid arthritis (RA) necessitated updating the European League Against Rheumatism (EULAR) RA management recommendations. A large international Task Force based decisions on evidence from 3 systematic literature reviews, developing 4 overarching principles and 12 recommendations (vs 3 and 14, respectively, in 2013). The recommendations address conventional synthetic (cs) disease-modifying antirheumatic drugs (DMARDs) (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GC); biological (b) DMARDs (tumour necrosis factor (TNF)-inhibitors (adalimumab, certoliz
APA, Harvard, Vancouver, ISO, and other styles
50

Al Mohamad, Fares, Valeria Rios Rodriguez, Hildrun Haibel, et al. "Association of nociplastic and neuropathic pain components with the presence of residual symptoms in patients with axial spondyloarthritis receiving biological disease-modifying antirheumatic drugs." RMD Open 10, no. 1 (2024): e004009. http://dx.doi.org/10.1136/rmdopen-2023-004009.

Full text
Abstract:
ObjectiveTo evaluate the association of nociplastic (NoP) and neuropathic pain (NP) components with residual symptoms in patients with radiographic axial spondyloarthritis (r-axSpA) receiving biological disease-modifying antirheumatic drugs (bDMARDs).Methods78 patients with r-axSpA from the GErman SPondyloarthritis Inception Cohort receiving a bDMARD for at least 3 months were included in this analysis. The Widespread Pain Index (WPI) and the PainDETECT (PD) questionnaire were used to quantify the NoP and the NP components, respectively. Axial Spondyloarthritis Disease Activity Score (ASDAS) a
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography